Furthest along
4 in Phase 2
3 in Phase 1
Next date
Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells, Phase 1 trial completes
Drugs
7
in active trials · 10 in all
Trials
6 active
10 since 2021
Drugs7
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 2 | 31 Mar 2027Phase 2 trial completes | |||
| Next date | 31 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | B-ALL | ||||
| Open drug page | |||||
— |
Phase 1/2 | 18 Aug 2027Phase 1/2 trial completes | |||
| Next date | 18 Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Autoimmune Diseases | ||||
| Open drug page | |||||
— |
Phase 1/2 | 1 Feb 2028Phase 1/2 trial completes | |||
| Next date | 1 Feb 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Multiple Myeloma in Relapse, Multiple Myeloma Refractory | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | T Lymphoblastic Leukemia/Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Mar 2027Phase 1 trial completes | |||
| Next date | 30 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors | ||||
| Open drug page | |||||
In vivo CLL-1 CAR-T, lentiviral |
Phase 1 | 31 Oct 2028Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 Oct 2028 · Phase 1 trial completes | ||||
| Also tested for | Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | ||||
| Open drug page | |||||
SENL101not checked |
— |
Phase 1 | — | ||
| Also tested for | T-lymphoblastic Lymphoma, T-ALL | ||||
| Open drug page | |||||
About
- No active trial
- Autologous aPD-L1 armored anti-CD22 CAR T cells, Autologous CD19-targeting CAR T cells, CD7 CAR-T
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021